Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years: https://g.foolcdn.com/editorial/images/772614/pharmacist-talking-to-patient.jpg
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its

Why Roche Holdings Stock Popped Today: https://g.foolcdn.com/editorial/images/772667/lady-scientist-in-lab-coat-and-goggles-pours-blue-liquid-from-a-test-tube-into-a-beaker.jpg
Why Roche Holdings Stock Popped Today

Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains.

Roche announced this morning that the U.S

AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2023http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2023
AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2023
1 Magnificent Dividend Stock to Buy and Hold: https://g.foolcdn.com/editorial/images/769890/patient-and-doctor-talking.jpg
1 Magnificent Dividend Stock to Buy and Hold

There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time

AEVIS VICTORIA SA (AEVS.SW) – Publication of the 2023 revenuehttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA (AEVS.SW) – Publication of the 2023 revenue
AEVIS VICTORIA SA (AEVS.SW) – Publication of the 2023 revenue
AEVIS VICTORIA SA  - Fabrice Zumbrunnen to become CEO of AEVIS VICTORIA SA as of May 1, 2024http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA - Fabrice Zumbrunnen to become CEO of AEVIS VICTORIA SA as of May 1, 2024
AEVIS VICTORIA SA - Fabrice Zumbrunnen to become CEO of AEVIS VICTORIA SA as of May 1, 2024
Harvard Business Professor on Failing Well: https://g.foolcdn.com/editorial/images/765894/mfm_18.jpg
Harvard Business Professor on Failing Well

In this podcast, Motley Fool host Deidre Woollard talks about the art of failing with Amy Edmondson, the Novartis Professor of Leadership and Management at the Harvard Business School, and author of

Novartis Ag (NVS) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q4 2023 Earnings CallJan 31, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know: https://g.foolcdn.com/editorial/images/758429/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know

In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks: https://g.foolcdn.com/editorial/images/757221/scientist-peers-into-microscope-in-laboratory.jpg
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks

On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most

AEVIS VICTORIA SA – Continued organic growth in the third quarter of 2023 http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Continued organic growth in the third quarter of 2023
AEVIS VICTORIA SA – Continued organic growth in the third quarter of 2023
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?: https://g.foolcdn.com/editorial/images/752299/group-of-medical-practitioners-having-a-seminar-in-board-room.jpg
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Healthcare companies are spending big on developing treatments for inflammatory bowel disease (IBD), which consists of either Crohn's disease or ulcerative colitis (UC), or both. The lure for IBD

2 Green Flags and 1 Red Flag for Novartis Stock: https://g.foolcdn.com/editorial/images/752126/scientists-high-five-smile.jpg
2 Green Flags and 1 Red Flag for Novartis Stock

Share prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular, immunology, neuroscience, solid tumors, and

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q3 2023 Earnings CallOct 24, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

2 Biotech Stocks That Could Make You Richer: https://g.foolcdn.com/editorial/images/750829/doctor-holding-elderly-patients-hand.jpg
2 Biotech Stocks That Could Make You Richer

Although sometimes risky and volatile, the biotech industry is an excellent place to find stocks that can generate steady returns for years. That's because these companies tend to offer products

3 Unstoppable Stocks to Buy and Hold for Decades: https://g.foolcdn.com/editorial/images/751020/advisor-reviewing-data-on-a-laptop-with-a-family.jpg
3 Unstoppable Stocks to Buy and Hold for Decades

Want to invest in stocks that you can buy and forget about? If so, you'll want to consider companies with plenty of long-term growth opportunities and solid financials. Among the best growth

AEVIS VICTORIA SA – Swiss Hotel Properties SA expands its real estate portfolio in Zermatthttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Swiss Hotel Properties SA expands its real estate portfolio in Zermatt
AEVIS VICTORIA SA – Swiss Hotel Properties SA expands its real estate portfolio in Zermatt
AEVIS VICTORIA SA – Publication of the half-year report 2023http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Publication of the half-year report 2023
AEVIS VICTORIA SA – Publication of the half-year report 2023
2 Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/746773/physician-talking-to-patient.jpg
2 Dividend Stocks to Buy and Hold Forever

Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown

Could This Medicine Be the Next Winner for Novartis?: https://g.foolcdn.com/editorial/images/744947/a-patient-attends-a-doctor-appointment.jpg
Could This Medicine Be the Next Winner for Novartis?

Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known

2 Top Biotech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/743787/a-doctor-examines-a-patient.jpg
2 Top Biotech Stocks to Buy Right Now

Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to

2 Stocks That Raised Their Guidance in July: https://g.foolcdn.com/editorial/images/740653/investor-checking-stocks-on-his-phone.jpg
2 Stocks That Raised Their Guidance in July

One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:

Should Income Investors Buy This Blue Chip Stock?: https://g.foolcdn.com/editorial/images/740451/a-customer-shops-at-a-pharmacy.jpg
Should Income Investors Buy This Blue Chip Stock?

For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an

Why Novartis Stock Spiked Today: https://g.foolcdn.com/editorial/images/740239/healthcare.jpg
Why Novartis Stock Spiked Today

Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock